Novo Integrated Sciences, Inc. (NVOS)
USD 0.0
(100.0%)
USD 0.0
(100.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -5.84 Million USD | 11.94% |
| 2022 | -22.47 Million USD | -157.72% |
| 2021 | -2.58 Million USD | 15.8% |
| 2020 | -2.78 Million USD | -1262.79% |
| 2019 | 130.44 Thousand USD | 85.38% |
| 2018 | -1.47 Million USD | -13192.11% |
| 2017 | -16.69 Thousand USD | 93.25% |
| 2016 | -164.88 Thousand USD | 58.84% |
| 2015 | -277.77 Thousand USD | -359.2% |
| 2014 | -87.23 Thousand USD | 71.54% |
| 2013 | -306.51 Thousand USD | 62.35% |
| 2012 | -989.9 Thousand USD | 63.34% |
| 2011 | -2.22 Million USD | 4.5% |
| 2010 | -2.32 Million USD | -17.8% |
| 2009 | -1.97 Million USD | -108.76% |
| 2008 | -945.39 Thousand USD | 61.78% |
| 2007 | -2.47 Million USD | -69.36% |
| 2006 | -1.46 Million USD | -36.92% |
| 2005 | -1.06 Million USD | -409.84% |
| 2004 | -209.22 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -1.96 Million USD | -992.57% |
| 2024 Q1 | -3.39 Million USD | -34.85% |
| 2024 Q2 | -1.27 Million USD | 67.79% |
| 2023 Q1 | -1.65 Million USD | 59.53% |
| 2023 Q4 | -1.89 Million USD | -140.95% |
| 2023 FY | - USD | 11.94% |
| 2023 Q3 | -788.43 Thousand USD | 36.0% |
| 2023 Q2 | -1.23 Million USD | 25.5% |
| 2022 FY | - USD | -157.72% |
| 2022 Q1 | -660.98 Thousand USD | 42.07% |
| 2022 Q4 | -4.08 Million USD | -1206.08% |
| 2022 Q3 | -312.79 Thousand USD | 76.63% |
| 2022 Q2 | -1.33 Million USD | -102.52% |
| 2021 Q1 | -391.23 Thousand USD | 85.92% |
| 2021 Q3 | -12.06 Thousand USD | 98.71% |
| 2021 Q4 | -1.14 Million USD | -9354.83% |
| 2021 FY | - USD | 15.8% |
| 2021 Q2 | -938.14 Thousand USD | -139.79% |
| 2020 FY | - USD | -1262.79% |
| 2020 Q1 | -28.71 Thousand USD | -115.26% |
| 2020 Q2 | -102.54 Thousand USD | -257.14% |
| 2020 Q3 | -39.06 Thousand USD | 61.9% |
| 2020 Q4 | -2.77 Million USD | -7010.94% |
| 2019 Q1 | -187.66 Thousand USD | -235.51% |
| 2019 FY | - USD | 85.38% |
| 2019 Q4 | 188.15 Thousand USD | 649.27% |
| 2019 Q2 | -50.52 Thousand USD | 73.08% |
| 2019 Q3 | -34.25 Thousand USD | 32.19% |
| 2018 FY | - USD | -13192.11% |
| 2018 Q4 | -55.93 Thousand USD | 64.41% |
| 2018 Q3 | -157.14 Thousand USD | 85.83% |
| 2018 Q2 | -1.1 Million USD | -604.85% |
| 2018 Q1 | -157.32 Thousand USD | -353.5% |
| 2017 FY | - USD | 93.25% |
| 2017 Q4 | 62.05 Thousand USD | 124.63% |
| 2017 Q3 | -251.98 Thousand USD | -580.61% |
| 2017 Q2 | -37.02 Thousand USD | 12.83% |
| 2017 Q1 | -42.47 Thousand USD | -13.86% |
| 2016 FY | - USD | 58.84% |
| 2016 Q4 | -37.3 Thousand USD | -118.78% |
| 2016 Q1 | 47.42 Thousand USD | 200.37% |
| 2016 Q2 | -68.06 Thousand USD | -243.51% |
| 2016 Q3 | -17.05 Thousand USD | 74.95% |
| 2015 Q2 | -44.65 Thousand USD | -157.07% |
| 2015 Q4 | -47.25 Thousand USD | 86.73% |
| 2015 FY | - USD | -359.2% |
| 2015 Q3 | -356.07 Thousand USD | -697.32% |
| 2015 Q1 | -17.37 Thousand USD | -72.0% |
| 2014 Q3 | -180.92 Thousand USD | -333.72% |
| 2014 FY | - USD | 71.54% |
| 2014 Q1 | -75.75 Thousand USD | 25.57% |
| 2014 Q2 | -41.71 Thousand USD | 44.93% |
| 2014 Q4 | -10.1 Thousand USD | 94.42% |
| 2013 FY | - USD | 62.35% |
| 2013 Q1 | 145.1 Thousand USD | 187.01% |
| 2013 Q2 | -99.69 Thousand USD | -168.71% |
| 2013 Q4 | -101.78 Thousand USD | 38.59% |
| 2013 Q3 | -165.74 Thousand USD | -66.25% |
| 2012 Q4 | -166.77 Thousand USD | 52.88% |
| 2012 Q3 | -353.93 Thousand USD | 11.76% |
| 2012 FY | - USD | 63.34% |
| 2012 Q1 | -407.72 Thousand USD | 18.63% |
| 2012 Q2 | -401.09 Thousand USD | 1.63% |
| 2011 FY | - USD | 4.5% |
| 2011 Q3 | -479.72 Thousand USD | 42.21% |
| 2011 Q4 | -501.05 Thousand USD | -4.45% |
| 2011 Q1 | -422.41 Thousand USD | -426.72% |
| 2011 Q2 | -830.12 Thousand USD | -96.52% |
| 2010 Q1 | -783.33 Thousand USD | -34.67% |
| 2010 Q4 | -80.19 Thousand USD | 93.14% |
| 2010 Q2 | -653.7 Thousand USD | 16.55% |
| 2010 Q3 | -1.16 Million USD | -78.77% |
| 2010 FY | - USD | -17.8% |
| 2009 Q3 | -319.08 Thousand USD | -10.2% |
| 2009 FY | - USD | -108.76% |
| 2009 Q4 | -581.68 Thousand USD | -82.3% |
| 2009 Q2 | -289.54 Thousand USD | 13.32% |
| 2009 Q1 | -334.06 Thousand USD | -26.22% |
| 2008 Q1 | -852.47 Thousand USD | -76.52% |
| 2008 Q4 | -264.67 Thousand USD | -52.95% |
| 2008 FY | - USD | 61.78% |
| 2008 Q2 | -173.61 Thousand USD | 79.63% |
| 2008 Q3 | -173.04 Thousand USD | 0.33% |
| 2007 Q4 | -482.92 Thousand USD | -4.12% |
| 2007 Q1 | -516.78 Thousand USD | 7.75% |
| 2007 Q3 | -463.82 Thousand USD | 31.23% |
| 2007 FY | - USD | -69.36% |
| 2007 Q2 | -674.4 Thousand USD | -30.5% |
| 2006 FY | - USD | -36.92% |
| 2006 Q3 | -258.76 Thousand USD | -107.28% |
| 2006 Q1 | -277.88 Thousand USD | -132.34% |
| 2006 Q2 | -124.83 Thousand USD | 55.08% |
| 2006 Q4 | -560.21 Thousand USD | -116.49% |
| 2005 FY | - USD | -409.84% |
| 2005 Q2 | -236.36 Thousand USD | 0.0% |
| 2005 Q4 | -119.6 Thousand USD | 72.37% |
| 2005 Q3 | -432.88 Thousand USD | -83.15% |
| 2004 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acadia Healthcare Company, Inc. | 189.11 Million USD | 103.093% |
| Addus HomeCare Corporation | 106.55 Million USD | 105.489% |
| AirSculpt Technologies, Inc. | 28.31 Million USD | 120.659% |
| Amedisys, Inc. | 216.91 Million USD | 102.696% |
| American Oncology Network, Inc. | -39.35 Million USD | 85.136% |
| Astrana Health, Inc. | 123.68 Million USD | 104.729% |
| Aveanna Healthcare Holdings Inc. | 44.34 Million USD | 113.189% |
| IMAC Holdings, Inc. | -5.94 Million USD | 1.644% |
| biote Corp. | 9.23 Million USD | 163.342% |
| Cryo-Cell International, Inc. | -10.41 Million USD | 43.853% |
| Cross Country Healthcare, Inc. | 129.33 Million USD | 104.522% |
| COMPASS Pathways plc | -123.8 Million USD | 95.276% |
| DocGo Inc. | 32.72 Million USD | 117.873% |
| The Ensign Group, Inc. | 353.23 Million USD | 101.656% |
| Healthcare Services Group, Inc. | 75.21 Million USD | 107.777% |
| InnovAge Holding Corp. | 1.15 Million USD | 606.846% |
| Assure Holdings Corp. | -19.82 Million USD | 70.495% |
| The Joint Corp. | 9.14 Million USD | 163.981% |
| LifeStance Health Group, Inc. | -104.92 Million USD | 94.426% |
| Mobile-health Network Solutions Class A Ordinary Shares | -15.55 Million USD | 62.397% |
| ModivCare Inc. | -26.75 Million USD | 78.135% |
| NewGenIvf Group Limited | 384.3 Thousand USD | 1621.968% |
| Option Care Health, Inc. | 376.79 Million USD | 101.552% |
| P3 Health Partners Inc. | -81.07 Million USD | 92.785% |
| P3 Health Partners Inc. | -81.07 Million USD | 92.785% |
| The Pennant Group, Inc. | 30.36 Million USD | 119.26% |
| Surgery Partners, Inc. | 446.1 Million USD | 101.311% |
| Syra Health Corp. Class A Common Stock | -2.83 Million USD | -106.25% |
| Talkspace, Inc. | -22.01 Million USD | 73.429% |
| Talkspace, Inc. | -22.01 Million USD | 73.429% |
| The Oncology Institute, Inc. | -70.45 Million USD | 91.698% |
| The Oncology Institute, Inc. | -70.45 Million USD | 91.698% |